<DOC>
	<DOCNO>NCT00766987</DOCNO>
	<brief_summary>Positron Emission Tomography ( PET ) non-invasive , unique nuclear imaging technique allow evaluation blood flow heart provide information cell activity specific organ heart brain . It also provide useful information management patient poor pump function heart , heart failure , coronary artery disease . A cardiac viability image look heart use glucose ( sugar ) The image process determines area heart alive ( viable - use sugar ) versus area heart scar tissue ( non-viable ) . F-18 fluorodeoxyglucose ( FDG ) radioactive substance use determine myocardial viability . This nuclear imaging technique show useful direct management patient care . The Ministry Health recognize clinical utility FDG PET image myocardial viability assessment cancer indication . Optimizing potential advantage FDG PET Ontario , require characterization patient population , referral pattern , upstream downstream resource utilization patient outcome . Therefore , registry study undertake provide specific information utility PET clinical situation Ontario . The propose registry facilitate monitoring implementation limit technology allow continue evaluation practice pattern outcomes . The University Ottawa Heart Institute coordinate centre project PET centre London , Hamilton Toronto also participate . The purpose study evaluate utility FDG PET viability image decision make process patient poor leave ventricular function may candidate revascularization study downstream effect clinical management decision . Patients meet specific inclusion criterion eligible study .</brief_summary>
	<brief_title>Cardiac FDG PET Viability Registry</brief_title>
	<detailed_description>Heart failure reduce leave ventricular function associate significant morbidity mortality although multiple trial involve medical device therapy show improved survival , overall mortality remain high . Therapeutic intervention study involve transplantation revascularization conclude patient viable myocardium revascularized approach often adopt high peri-operative morbidity mortality . Due factor need good approach define select patient severe ventricular dysfunction . FDG PET study date consistently show patient viable myocardium FDG PET high risk cardiac event death undergo timely revascularization . FDG PET viability data impact decision make patient severe leave ventricular ( LV ) dysfunction benefit early revascularization see patient ischemic viable myocardium . The accuracy FDG PET predict regional global LV function recovery , utility decision make ability identify high risk patient demonstrate . These finding support clinical role FDG PET assess select patient CAD severe LV function . The Cardiac FDG PET Registry ( CADRE ) provide specific information utility PET clinical situation . To knowledge large multi-centre FDG PET myocardial viability registry . The registry facilitate monitoring evaluation practise pattern , upstream downstream resource utilization ( diagnostic imaging revascularization ) outcomes relate severity abnormality detect . The impact FDG PET parameter outcome measure compare clinical parameter . These finding optimize implementation technology clinical practise Ontario identify parameter FDG PET predict adverse outcome specific patient population . The result registry impact clinical practise health care patient Ontario internationally . 3 . Research Plan Objectives : 1 . To develop registry patient undergo FDG PET assessment myocardial viability 2 . To determine upstream downstream resource utilization ( diagnostic imaging revascularization ) patient undergo FDG PET 3 . To determine outcome patient undergo PET image relate outcome severity abnormality detect . 4 . To determine impact FDG PET parameter outcome measure compare clinical parameter . Methods : Consent obtain eligible subject . Data collect prospective manner evaluate patient , meet inclusion criterion , undergo cardiac PET imaging . Physicians Ontario notify via Ontario Medical association ( OMA ) Cardiovascular Care Network FDG PET viability image clinically available appropriate patient provincial registry . The participate registry site well indication FDG PET viability imaging circulate . Health Canada require patient undergo image positron emit radiopharmaceutical ( PERs ) must partake research protocol , therefore patient wish participate CADRE study , second consent provide collection baseline safety data , ie image parameter , tracer dose adverse effect .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>Patients ischemic leave ventricular dysfunction moderate severe range ( previous assessment ventricular function leave ventricular ejection fraction ( LVEF ) approximately 35 % Patients possible candidate revascularization sufficient viable myocardium identify consider heart transplantation viable myocardium Patients New York Heart Association ( NYHA ) Canadian Cardiovascular Society ( CCS ) Class II IV symptom despite maximal medical therapy . Under 18 year age Pregnant lactating female Already know ineligible revascularization cardiac transplantation Unable lie supine image PET Unable take insulin ( eg . severe hypokalemia ) Failure obtain informed consent Claustrophobia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>FDG PET viability image</keyword>
	<keyword>morbidity mortality</keyword>
	<keyword>revascularization</keyword>
	<keyword>resource utilization</keyword>
</DOC>